Brentuximab vedotin may improve overall survival in patients with Hodgkin Lymphoma

ROCHESTER, Minn. — A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma, when compared to the current standard of chemotherapy alone. Results of the r esearch were presented by Stephen Ansell, M.D., Ph.D., at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago and were published today in the New England…
Source: Mayo Clinic Minnesota News - Category: Hospital Management Source Type: news